FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3151043580> ?p ?o ?g. }

• W3151043580 abstract "We investigated the prognostic usefulness of prechemoradiotherapy (CRT) albumin-to-alkaline phosphatase ratio (AAPR) in unresectable locally advanced pancreatic adenocarcinoma (LAPAC) patients managed with definitive concurrent CRT (CCRT).A sum of 136 LAPAC patients who consecutively underwent definitive CCRT was retrospectively analyzed. The AAPR (serum albumin (g/dL)/serum alkaline phosphatase (IU/L)) was calculated by using the parameters obtained from the routine biochemistry tests on the first day of the CCRT. Ideal AAPR cutoff was sought by utilizing receiver operating characteristic (ROC) curve analysis. The primary and secondary endpoints were the impact of the AAPR on the overall survival (OS) and progression-free survival (PFS) results, respectively.At a median follow-up of 14.8 months (range: 3.2-85.7), the median PFS and OS times were 7.5 (95% confidence interval (CI): 6.0-9.0) and 14.9 months (95% CI: 11.9-17.9), respectively. The ideal common AAPR cutoff was identified at the rounded 0.46 (area under the curve: 72.3%; sensitivity: 71.2%; specificity: 70.3%) point that dichotomized the patients into two groups: low AAPR (L-AAPR; N = 71) and high AAPR (H-AAPR; N = 65) groups, respectively. Comparative survival analyses showed that the L-AAPR cohort had significantly shorter median PFS (6.8 (95% CI: 5.7-7.9) versus 11.3 (95% CI: 9.9-12.7) months; P = 0.005) and OS (12.8 (95% CI: 10.6-15.0) versus 19.2 (95% CI: 16.9-21.5) months; P = 0.001) durations than their H-AAPR counterparts, separately. Albeit the N1-2 (P = 0.004) and CA 19-9 > 90 U/mL (P = 0.008) were also found to be associated with inferior outcomes, yet the results of the multivariate analyses ascertained the L-AAPR as an independent indicator of diminished PFS (P = 0.003) and OS (P = 0.002) results.The present results proposed that the pretreatment AAPR < 0.46 was a novel independent indicator of adverse PFS and OS in unresectable LAPAC patients undergoing definitive CCRT." @default.
• W3151043580 created "2021-04-13" @default.
• W3151043580 creator A5002758866 @default.
• W3151043580 creator A5064628495 @default.
• W3151043580 date "2021-04-08" @default.
• W3151043580 modified "2023-09-27" @default.
• W3151043580 title "Prognostic Utility of Prechemoradiotherapy Albumin-to-Alkaline Phosphatase Ratio in Unresectable Locally Advanced Pancreatic Carcinoma Patients" @default.
• W3151043580 cites W1875224590 @default.
• W3151043580 cites W1965037168 @default.
• W3151043580 cites W1979598229 @default.
• W3151043580 cites W1982024468 @default.
• W3151043580 cites W1984052587 @default.
• W3151043580 cites W1995546722 @default.
• W3151043580 cites W1995879127 @default.
• W3151043580 cites W2006957711 @default.
• W3151043580 cites W2020491943 @default.
• W3151043580 cites W2031079883 @default.
• W3151043580 cites W2034267351 @default.
• W3151043580 cites W2041487550 @default.
• W3151043580 cites W2044783056 @default.
• W3151043580 cites W2048270768 @default.
• W3151043580 cites W2050740769 @default.
• W3151043580 cites W2066052326 @default.
• W3151043580 cites W2068500751 @default.
• W3151043580 cites W2108549165 @default.
• W3151043580 cites W2109141563 @default.
• W3151043580 cites W2117692326 @default.
• W3151043580 cites W2129197203 @default.
• W3151043580 cites W2132556072 @default.
• W3151043580 cites W2133658709 @default.
• W3151043580 cites W2136150034 @default.
• W3151043580 cites W2345885627 @default.
• W3151043580 cites W2411143367 @default.
• W3151043580 cites W2413386818 @default.
• W3151043580 cites W2562047649 @default.
• W3151043580 cites W2613196848 @default.
• W3151043580 cites W2747294052 @default.
• W3151043580 cites W2759471592 @default.
• W3151043580 cites W2766919581 @default.
• W3151043580 cites W2886128972 @default.
• W3151043580 cites W2908555171 @default.
• W3151043580 cites W2910957193 @default.
• W3151043580 cites W2912635537 @default.
• W3151043580 cites W2916589624 @default.
• W3151043580 cites W2932794400 @default.
• W3151043580 cites W2946832024 @default.
• W3151043580 cites W2948830242 @default.
• W3151043580 cites W2961750526 @default.
• W3151043580 cites W2972538962 @default.
• W3151043580 cites W2978439447 @default.
• W3151043580 cites W2989923235 @default.
• W3151043580 cites W2999417355 @default.
• W3151043580 cites W3005419541 @default.
• W3151043580 cites W3010601690 @default.
• W3151043580 cites W3033919932 @default.
• W3151043580 cites W3042568371 @default.
• W3151043580 cites W3045887693 @default.
• W3151043580 cites W3046509007 @default.
• W3151043580 cites W3080173125 @default.
• W3151043580 cites W3084430921 @default.
• W3151043580 doi "https://doi.org/10.1155/2021/6647145" @default.
• W3151043580 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8049825" @default.
• W3151043580 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33927759" @default.
• W3151043580 hasPublicationYear "2021" @default.
• W3151043580 type Work @default.
• W3151043580 sameAs 3151043580 @default.
• W3151043580 citedByCount "3" @default.
• W3151043580 countsByYear W31510435802021 @default.
• W3151043580 countsByYear W31510435802022 @default.
• W3151043580 crossrefType "journal-article" @default.
• W3151043580 hasAuthorship W3151043580A5002758866 @default.
• W3151043580 hasAuthorship W3151043580A5064628495 @default.
• W3151043580 hasBestOaLocation W31510435801 @default.
• W3151043580 hasConcept C121332964 @default.
• W3151043580 hasConcept C121608353 @default.
• W3151043580 hasConcept C126322002 @default.
• W3151043580 hasConcept C160160445 @default.
• W3151043580 hasConcept C181199279 @default.
• W3151043580 hasConcept C2776125364 @default.
• W3151043580 hasConcept C2778217198 @default.
• W3151043580 hasConcept C2780210213 @default.
• W3151043580 hasConcept C2992026798 @default.
• W3151043580 hasConcept C44249647 @default.
• W3151043580 hasConcept C55493867 @default.
• W3151043580 hasConcept C58471807 @default.
• W3151043580 hasConcept C62520636 @default.
• W3151043580 hasConcept C71924100 @default.
• W3151043580 hasConcept C86803240 @default.
• W3151043580 hasConcept C90924648 @default.
• W3151043580 hasConceptScore W3151043580C121332964 @default.
• W3151043580 hasConceptScore W3151043580C121608353 @default.
• W3151043580 hasConceptScore W3151043580C126322002 @default.
• W3151043580 hasConceptScore W3151043580C160160445 @default.
• W3151043580 hasConceptScore W3151043580C181199279 @default.
• W3151043580 hasConceptScore W3151043580C2776125364 @default.
• W3151043580 hasConceptScore W3151043580C2778217198 @default.
• W3151043580 hasConceptScore W3151043580C2780210213 @default.
• W3151043580 hasConceptScore W3151043580C2992026798 @default.
• W3151043580 hasConceptScore W3151043580C44249647 @default.
• W3151043580 hasConceptScore W3151043580C55493867 @default.

• next